Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction

American Journal of Cardiology

Volumn 81, Issue 5, 1998, Pages 531-537

  Wang, Tzung Dau ^b   Wu, Chau Chung ^b   Chen, Wen Jone ^b   Lee, Chii Ming ^b   Chen, Ming Fong ^b   Liau, Chiau Suong ^b   Sung, Fung Chang ^b   Lee, Yuan Teh ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGED; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CREATINE KINASE; FEMALE; GATED BLOOD-POOL IMAGING; HUMANS; HYPERLIPIDEMIAS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE VOLUME; SYSTOLE; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 0032032962     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00974-0     Document Type: Article

References (21)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering therapy in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Isles CG, Lorimer AR, MacFarlane PN, Mckillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
4. Brown G, Albers JJ, Fisher LD, Sheafer SAM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
5. Lars Bastiaanse EM, Atsma DE, Kuijpers MMC, Van der Laarse A. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys 1994;313:58-63.
6. Tanner FC, Noll G, Boulanuk CM, Luscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary artery: role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991;83:2012-2020.
7. Anderson TJ, Meredith IT, Yeung AC, Charbonneau F, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-1650.
8. Golino P, Maroko PR, Carew TE. Efficacy of platelet depletion in counter-acting the detrimental effect of acute hypercholesterolemia on infarct size and the no-reflow phenomenon in rabbits undergoing coronary artery occlusion-reperfusion. Circulation 1987;76:173-180.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotien cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
10. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1983;28:1039-1057.
11. The TIMI Study Group. The thrombolysis on myocardial infarction trial. N Engl J Med 1985;312:932-936.
12. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LSC. A reporting system on patients evaluated for coronary artery disease. Circulation 1975;51(suppl):5-40.
13. Gensini G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606.
14. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. Am J Cardiol 1967;20:457-464.
15. Rosenson RS. Myocardial injury: the acute phase response and lipoprotien metabolism. J Am Coll Cardiol 1993;22:933-940.
16. Becker RC, Corrao JM, Lew R, Bradley J, Queenan J. Relationship between serum total cholesterol, infarct size, and early clinical outcome following acute myocardial infarction. Cardiology 1992;80:65-70.
17. Chen MF, Lee YT, Hsu HC, Yeh PC, Liau CS, Huang PC. Effect of dietary supplementation with fish oil on atherosclerosis and myocardial injury during acute coronary occlusion-reperfusion in diet-induced hypercholesterolemic rabbits. Int J Cardiol 1992;35:323-331.
18. Chilian WM. Coronary microcirculation in health and disease. Circulation 1997;95:522-528.
19. Fuster V. Elucidation of the role of plague instability and rupture in acute coronary events. Am J Cardiol 1995;76(suppl C):24C-33C.
20. Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vase Biol 1996;16:539-545.
21. Yeagle PL. Lipid regulation of cell membrane structure and function. FASEB J 1989;3:1833-1842.